AU2018290983B2 - Methods of treating heart failure with cardiac sarcomere activators - Google Patents

Methods of treating heart failure with cardiac sarcomere activators Download PDF

Info

Publication number
AU2018290983B2
AU2018290983B2 AU2018290983A AU2018290983A AU2018290983B2 AU 2018290983 B2 AU2018290983 B2 AU 2018290983B2 AU 2018290983 A AU2018290983 A AU 2018290983A AU 2018290983 A AU2018290983 A AU 2018290983A AU 2018290983 B2 AU2018290983 B2 AU 2018290983B2
Authority
AU
Australia
Prior art keywords
dose
subject
csa
plasma concentration
initial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018290983A
Other languages
English (en)
Other versions
AU2018290983A1 (en
Inventor
Narimon HONARPOUR
Fady Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Cytokinetics Inc
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of AU2018290983A1 publication Critical patent/AU2018290983A1/en
Application granted granted Critical
Publication of AU2018290983B2 publication Critical patent/AU2018290983B2/en
Priority to AU2024200991A priority Critical patent/AU2024200991B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018290983A 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators Active AU2018290983B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200991A AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200991A Division AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Publications (2)

Publication Number Publication Date
AU2018290983A1 AU2018290983A1 (en) 2020-01-23
AU2018290983B2 true AU2018290983B2 (en) 2023-11-23

Family

ID=63013097

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018290983A Active AU2018290983B2 (en) 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators
AU2024200991A Active AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200991A Active AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Country Status (22)

Country Link
US (4) US11576910B2 (enExample)
EP (2) EP3645002B1 (enExample)
JP (3) JP2020526483A (enExample)
CN (1) CN110996953A (enExample)
AU (2) AU2018290983B2 (enExample)
BR (1) BR112019028046A2 (enExample)
CA (1) CA3068588A1 (enExample)
DK (1) DK3645002T3 (enExample)
ES (1) ES3008457T3 (enExample)
FI (1) FI3645002T3 (enExample)
HR (1) HRP20241729T1 (enExample)
HU (1) HUE069805T2 (enExample)
LT (1) LT3645002T (enExample)
MA (1) MA49508B1 (enExample)
MD (1) MD3645002T2 (enExample)
MX (2) MX2020000190A (enExample)
PL (1) PL3645002T3 (enExample)
PT (1) PT3645002T (enExample)
RS (1) RS66581B1 (enExample)
SI (1) SI3645002T1 (enExample)
SM (1) SMT202500067T1 (enExample)
WO (1) WO2019006235A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
IL270663B (en) 2017-06-30 2022-08-01 Amgen Inc Synthesis of omecamtib from carbyl
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
ES2815899T3 (es) 2018-07-09 2021-03-31 Fis Fabbrica Italiana Sintetici Spa 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
IL295490A (en) * 2020-02-10 2022-10-01 Amgen Inc omecamtiv mecarbil tablet
CA3180943A1 (en) * 2020-06-15 2021-12-23 Jean-Francois TAMBY Treatment of atrial dysfunction
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
WO2022103966A1 (en) 2020-11-12 2022-05-19 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
AU2024248193A1 (en) 2023-03-27 2025-10-09 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210240A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
KR20010040819A (ko) 1998-02-10 2001-05-15 가마꾸라 아끼오 제어방출형 제제
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
NZ552404A (en) 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
WO2007133747A2 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
RU2422134C1 (ru) 2007-04-19 2011-06-27 Донг-А Фармасьютикал. Ко., Лтд Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
ES2733340T3 (es) * 2013-03-14 2019-11-28 Amgen Inc Compuestos heterocíclicos y sus usos
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN110603049A (zh) 2017-02-06 2019-12-20 阿塞勒隆制药公司 用于治疗心力衰竭的组合物和方法
IL270663B (en) 2017-06-30 2022-08-01 Amgen Inc Synthesis of omecamtib from carbyl
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
ES2815899T3 (es) 2018-07-09 2021-03-31 Fis Fabbrica Italiana Sintetici Spa 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
DK3599243T3 (da) 2018-07-26 2023-07-10 Cvie Therapeutics Ltd 17beta-heterocyklyl-digitalis-lignende forbindelser til behandlingen af hjertesvigt
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
EP3934654A1 (en) 2019-03-05 2022-01-12 Windtree Therapeutics, Inc. Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
WO2021070124A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
BR112022008641A2 (pt) 2019-11-10 2022-09-13 Myokardia Inc Métodos de tratamento com modulador de miosina
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
IL295490A (en) 2020-02-10 2022-10-01 Amgen Inc omecamtiv mecarbil tablet
WO2022103966A1 (en) 2020-11-12 2022-05-19 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210240A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Liu CL., et al., "Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure", Expert Opin Investig Drugs, 2016 vol. 25, no. 1, pages 117 - 127 *
Teerlink JR., et al., "Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure The ATOMIC-AHF Study", Jnl Am Co Card, 2016, vol. 67, no. 12, pages 1444 - 1455 *
Teerlink JR., et al., "Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial", Lancet, 2016, vol. 388, no. 10062, pages 2895 - 2903 *

Also Published As

Publication number Publication date
LT3645002T (lt) 2025-02-10
US20230149394A1 (en) 2023-05-18
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
CA3068588A1 (en) 2019-01-03
US20250255862A1 (en) 2025-08-14
SMT202500067T1 (it) 2025-03-12
HUE069805T2 (hu) 2025-04-28
RS66581B1 (sr) 2025-04-30
US11576910B2 (en) 2023-02-14
US12295952B2 (en) 2025-05-13
FI3645002T3 (fi) 2025-01-29
JP2023088944A (ja) 2023-06-27
ES3008457T3 (en) 2025-03-24
PT3645002T (pt) 2025-01-24
EP4512470A2 (en) 2025-02-26
AU2024200991A1 (en) 2024-03-07
US20200155547A1 (en) 2020-05-21
MD3645002T2 (ro) 2025-04-30
CN110996953A (zh) 2020-04-10
US11931358B2 (en) 2024-03-19
HRP20241729T1 (hr) 2025-03-14
JP2025165979A (ja) 2025-11-05
JP2020526483A (ja) 2020-08-31
MX2022015115A (es) 2023-01-18
US20230355615A1 (en) 2023-11-09
DK3645002T3 (da) 2024-12-16
EP3645002B1 (en) 2024-10-30
WO2019006235A1 (en) 2019-01-03
PL3645002T3 (pl) 2025-03-24
EP4512470A3 (en) 2025-04-23
AU2024200991B2 (en) 2025-04-10
SI3645002T1 (sl) 2025-03-31
MX2020000190A (es) 2020-07-22
MA49508A (fr) 2020-05-06
EP3645002A1 (en) 2020-05-06
MA49508B1 (fr) 2024-12-31

Similar Documents

Publication Publication Date Title
AU2024200991B2 (en) Methods of treating heart failure with cardiac sarcomere activators
Sayin et al. Left ventricular hypertrophy: etiology-based therapeutic options
JP2024500616A (ja) オメカムチブメカルビルの投与により心不全を処置する方法
EP3411021B1 (en) New use of a combination of sacubitril and valsartan
Bernier et al. Cardiac myosin activation for the treatment of systolic heart failure
Yuyun et al. Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review
Cada et al. Sacubitril/valsartan
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
HK40027649A (en) Methods of treating heart failure with cardiac sarcomere activators
US20210177803A1 (en) New pharmaceutical use for the treatment of heart failure
Silva Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan
Bozorgnia et al. Current management of heart failure: when to refer to heart failure specialist and when hospice is the best option
Ahmed et al. Sacubitril/Valsartan: A Novel Approach in the Treatment of Heart Failure with Reduced Ejection Fraction
Mystakidou FACULTY OF HEALTH SCIENCES
Finimundi et al. Effect of diuretic therapy on exercise capacity in patients with chronic angina and preserved left ventricular function
Hamdy et al. Why Pillar Directed Therapy Does Not Provide Absolute Protection in Heart Failure? The Five Pillars of the Management of Heart Failure

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HONARPOUR, NARIMON AND MALIK, FADY

FGA Letters patent sealed or granted (standard patent)